Get started
Author

David Drobne

Observed names: D Drobne, D. Drobne, Drobne, David
ORCID: 0000-0003-2734-675X
Observed ORCID: 0000-0003-2734-675X
OpenAlex ID: A5033719787
Risankizumab for Ulcerative Colitis
2024 · Edouard Louis, Stefan Schreiber, et al. · JAMA · 134
PDF
Early Trough Levels and Antibodies to Infliximab Predict Safety and Success of Reinitiation of Infliximab Therapy
2014 · Filip Baert, David Drobne, et al. · Clinical Gastroenterology and Hepatology · 134
PDF
Withdrawal of Immunomodulators After Co-treatment Does Not Reduce Trough Level of Infliximab in Patients With Crohn’s Disease
2014 · David Drobne, Peter Bossuyt, et al. · Clinical Gastroenterology and Hepatology · 132
Oxidative stress-related biomarkers as promising indicators of inflammatory bowel disease activity: A systematic review and meta-analysis
2024 · Armando Tratenšek, Igor Locatelli, et al. · Redox Biology · 105
Effectiveness of ustekinumab dose escalation in Crohn’s disease patients with insufficient response to standard‐dose subcutaneous maintenance therapy
2020 · Uri Kopylov, Jurij Hanzel, et al. · Alimentary Pharmacology & Therapeutics · 78
PDF
Down‐regulation of micro RNA s of the miR‐200 family and up‐regulation of Snail and Slug in inflammatory bowel diseases — hallmark of epithelial−mesenchymal transition
2016 · Nina Zidar, Emanuela Boštjančič, et al. · Journal of Cellular and Molecular Medicine · 69
PDF
Endoscopic Postoperative Recurrence in Crohn’s Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study
2022 · Henit Yanai, Anna Kagramanova, et al. · Journal of Crohn s and Colitis · 64
PDF
Intravenous versus subcutaneous delivery of biotherapeutics in IBD: an expert’s and patient’s perspective
2021 · Laimas Jonaitis, Srdjan Marković, et al. · BMC Proceedings · 51
PDF
Peak Concentrations of Ustekinumab After Intravenous Induction Therapy Identify Patients With Crohn’s Disease Likely to Achieve Endoscopic and Biochemical Remission
2020 · Jurij Hanžel, Jurij Zdovc, et al. · Clinical Gastroenterology and Hepatology · 51
Success and safety of high infliximab trough levels in inflammatory bowel disease
2018 · David Drobne, Tina Kurent, et al. · Scandinavian Journal of Gastroenterology · 46
Pathology of Fibrosis in Crohn's Disease—Contribution to Understanding Its Pathogenesis
2020 · Nina Zidar, Cord Langner, et al. · Frontiers in Medicine · 41
PDF
Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease
2019 · David Drobne, Tina Kurent, et al. · Alimentary Pharmacology & Therapeutics · 40
Impact of Infliximab and Cyclosporine on the Risk of Colectomy in Hospitalized Patients with Ulcerative Colitis Complicated by Cytomegalovirus—A Multicenter Retrospective Study
2017 · Uri Kopylov, Konstantinos Papamichael, et al. · Inflammatory Bowel Diseases · 39
Dose optimisation for Loss of Response to Vedolizumab— Pharmacokinetics and Immune Mechanisms
2021 · Bella Ungar, Karin Malickova, et al. · Journal of Crohn s and Colitis · 35
Acute biliary pancreatitis: detection of common bile duct stones with endoscopic ultrasound
2008 · Borut Štabuc, David Drobne, et al. · European Journal of Gastroenterology & Hepatology · 33
Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease
2019 · Jurij Hanžel, Nejc Sever, et al. · United European Gastroenterology Journal · 29
PDF
Ustekinumab Dosing Individualization in Crohn’s Disease Guided by a Population Pharmacokinetic–Pharmacodynamic Model
2021 · Jurij Aguiar Zdovc, Jurij Hanžel, et al. · Pharmaceutics · 27
PDF
A Population Pharmacokinetic and Exposure–Response Model of Golimumab for Targeting Endoscopic Remission in Patients With Ulcerative Colitis
2019 · Erwin Dreesen, Wannee Kantasiripitak, et al. · Inflammatory Bowel Diseases · 19
PDF
Real-Life Efficacy of Tofacitinib in Various Situations in Ulcerative Colitis: A Retrospective Worldwide Multicenter Collaborative Study
2023 · Tamás Resál, Péter Bacsur, et al. · Inflammatory Bowel Diseases · 15
PDF
OP10 Importance of trough levels and antibodies on the long-term efficacy of infliximab therapy in ulcerative colitis
2012 · M.T. Arias, N. Van de Casteele, et al. · Journal of Crohn s and Colitis · 14
PDF
Effectiveness of Third-Class Biologic Treatment in Crohn’s Disease: A Multi-Center Retrospective Cohort Study
2021 · Ahmad Albshesh, Joshua Taylor, et al. · Journal of Clinical Medicine · 13
PDF
Contemporary Management of Postoperative Crohn’s Disease after Ileocolonic Resection
2022 · Jurij Hanzel, David Drobne · Journal of Clinical Medicine · 11
PDF
Endoscopic remission can be predicted by golimumab concentrations in patients with ulcerative colitis treated with the changed label
2020 · Sebastian Stefanovic, Iris Detrez, et al. · European Journal of Gastroenterology & Hepatology · 11
Determination of 6-thioguanine and 6-methylmercaptopurine in dried blood spots using liquid chromatography-tandem mass spectrometry: Method development, validation and clinical application
2019 · Kristina Lampič, Jurij Trontelj, et al. · Clinica Chimica Acta · 11
Crohn's Disease: Infliximab Trough Levels and CRP During Infliximab-Immunomodulator Combination Treatment Are Associated With Clinical Outcome After Immunomodulator Withdrawal
2011 · David Drobne, Peter J. Bossuyt, et al. · Gastroenterology · 11
PDF
Works count: 123
Citation count: 1,376
H-index: 18
I10-index: 27
Year
Topic
Type